Health  Vol.6 No.5 , February 2014
Women with overweight, mixed hyperlipidemia, intolerance to glucose and diastolic hypertension
Abstract: Primarily healthy women who attended a practice of General Medicine were examined and coded data were evaluated using two statistical methods (n = 248, aged 36 ± 14 years). It was found that participants with LDL-related (mixed) hyperlipidemia showed higher blood pressure, a higher proportion of alcohol problems and/or smoking compared to normolipidemic women (p ≤ 0.05). These hyperlipidemic women who reported alcohol problems and/or smoking more often showed proteinuria and/or hematuria, rise of LDL/HDL, critical fasting blood glucose and lower HDL-cholesterol compared to hyperlipidemic women reporting healthy life (p ≤ 0.05). Likewise, high triglycerides were associated with rise of blood pressure and intolerance to glucose (p ≤ 0.05) and also with elevated total cholesterol. Alcohol-related hypertriglyceridemia overlapped with diastolic hypertension, rise of body weight and urine pathology, lowering of HDL-cholesterol and critical fasting blood glucose. The motivating message was that women with mixed hyperlipidemia and healthy life had functionally renal endothelium and healthy HDL-related baseline measures. Altogether, LDL-related hyperlipidemia and/or high triglycerides were correlated with diastolic hypertension whereby critical alcohol consumption declined renal endothelium and lowered HDL-cholesterol implicating baseline strategies to neutralize early risk factors.
Cite this paper: Korth, R. (2014) Women with overweight, mixed hyperlipidemia, intolerance to glucose and diastolic hypertension. Health, 6, 454-467. doi: 10.4236/health.2014.65064.

[1]   Korth, R., Zimmermann, K. and Richter, W. (1994) Lipo-protein-associated paf (LA-paf) was found in washed human platelets and monocyte-macrophage-like U937 cells. Chemistry Physics of Lipids, 70, 109-119.

[2]   Korth, R.M., Hirafuji, M., Benveniste, J. and Russo-Marie, F. (1995) Human umbilical vein endothelial cells: Specific binding of platelet-activating factor and cytosolic calcium flux. Biochemical Pharmacology, 49, 1793-1799.

[3]   Korth, R.M. (1997) Specific binding sites for 1-O-alkyl-sn-glyceryl-3-phosphorylcholine on intact human blood neutrophils. International Archives of Allergy and Immunology, 113, 460-464.

[4]   Korth, R.M. (2000) Comparison of phosphocholines in human plasma and cerebrospinal fluid (CSF). Faseb Journal, 14, A72.

[5]   Korth, R.M. (2002) AHA-syndromes. Chemistry and Physics of Lipids, 118, 96-97.

[6]   Korth, R.M. (2006) Gender obesity, alcohol use, hyperlipidemia, hypertension and declined renal endothelial barriers. Journal Men’s Health and Gender JMHG, 3, 279-289.

[7]   Solbu, M., Kronborg, J., Erikson, B.O., Jenssen, T.G. and Toft, I, (2008) Cardiovascular risk-factors predict progression of urinary albumin-excretion in a general, non-diabetic population. A gender-specific follow-up study. Atherosclerosis, 201, 398-406.

[8]   Vasan, R.S. (2005) Relative importance of borderline and elevated levels of coronary heart disease risk factors. Annals Internal Medicine, 142, 393-402.

[9]   Barzilay, J.J., Peterson, D., Cushman, M., Heckbert, S.R., Cao, J.J., Blaum, C., Tracy, R.P., Klein, R. and Herrington, D.M. (2004) The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension. The Cardiovascular Health Study. American Kidney Disease, 44, 25-34.

[10]   Maas, R., Schulze, F., Baumert, J., Löwel, H., Hamraz, K., Schwedhelm, E., Koenig and W., Böger, R.H. (2007) Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: Prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and Experimental Data. Clinical Chemistry, 53, 693-701.

[11]   Fröhlich, M., Sund, M., Lowel, H., Imhof, A., Hoffmeister, A. and Koenig. W. (2003) Independent associations of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA) Augsburg Survey 1994/1995). European Heart Journal, 24, 1365-1372.

[12]   Patja, K., Jousilahti, P., Hu, G., Valle, T., Quiao, Q. and Tuomilehto, J. (2005) Effects of smoking, obesity and physical activity on the risk of type 2 diabetes in middle-aged Finnish men and women. Journal Internal Medicine, 258, 356-362.

[13]   Su, J., Georgiades, A., Wu, R., Thulin, T., de Faire, U., Frostegard, J. (2006) Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis, 188, 160-166.

[14]   Kristjansson, K., Ljungmann, S., Bengtsson, C., Björkel, C. and Sigurdsson, J.A (2001) Microproteinuria and longterm prognosis with respect to renal function and survival in normotensive and hypertensive women. Scandinavian Journal Urology Nephrology, 35, 63-70.

[15]   Wu, R., Lemne, C., De Faire, U. and Frostegard, J. (1997) Antibodies to platelet-activating factor are associated with borderline hypertension, early atherosclerosis and the metabolic syndrome. Journal Internal Medicine, 246, 389-397.

[16]   Wohlin, M., Sundström, J., Ärnlöv, J., Andrén, B., Zethelius, B. and Lind L. (2003) Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men. Atherosclerosis, 170, 181-183.

[17]   Erkkilä, A.T., Närvänen, O., Lehto, S., Uusitupa, M.I.J. and Ylä-Herttiala, S. (2005) Antibodies against oxidized LDL and cardiolipin and mortality in patients with coronary heart disease. Atherosclerosis, 183, 157-162.

[18]   Fujimura Y, Hwang PM, Trout H, Kozloff L, Imaizumi M, Innis RB and Fujita M. (2008) Increased peripheral benzodiazepine receptors in arterial plaques of patients with arteriosclerosis: An autoradiographic study with [3H] PK11195. Atherosclerosis, 201, 108-111.

[19]   Korth, R., Hirafuji, M., Lalau Keraly, C., Delautier, D., Bidault, J. and Benveniste, J. (1989) Interaction of the paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells. British Journal Pharmacology, 98, 653-661.

[20]   Korth, R. and Middeke, M. (1991) Long time incubation of monocytic U 937 cells with LDL increase specific PAF-acether binding and the cellular acetylhy-drolase activity. Chemistry Physics of Lipids, 59, 207-213.

[21]   Korth, R.M. (2012) Two male study groups with adiposity and hypertriglyceridemia were at risk for hypertension and alcohol use decline renal endothelium. Health, 4, 1413-1419.

[22]   Korth, R. and Benveniste J. (1988) BN 52021 displaces [3H]paf-acether from, and inhibits its binding to intact human platelets. European Journal Pharmacology, 142, 331-341.

[23]   Korth, R., Bidault, J., Palmatier, R., Benveniste, J. and Ninio, E. (1993) Human platelets release a paf-acether: Acetylhydrolase similar to that in plasma. Lipids, 28, 193-199.

[24]   Frei, B., Stocker, R. and Ames, B.N. (1988) Antioxidant defenses and lipid perioxidation in human plasma. Proceedings. National Academy of Science, 85, 9748-9752.

[25]   Korth, R.M. (1997) VLDL and PAF binding to human endothelial cells. Chemistry and Physics of Lipids, 88, 134.

[26]   Korth, R.M. (2007) Novel compositions against al-kyl-acyl-GPC, the derivatives and products thereof. Publ. No. WO 2007/073727.

[27]   Faure, P., Troncy, L., Lecomte, M., Wiernsperger, N. Lagarde, M., Ruggerio, D. and Halimi, S., (2005) Albumin antioxidant capacity is modified by methylglyoxal. Diabetes & Metabolism, 31, 169-177.

[28]   Uribarri, J., Woodruff, S., Goodman, S., Cai, W., Chen, X., Pyzik, R., Yong, A., Striker, G.E. and Vlassara, H. (2010) Advance glycation end products in Foods and a practical Guide to their reduction in the diet. Journal American Dietary Association, 110, 911-916.

[29]   Chen, H.C. (2001) Molecular Mechanisms of sterol absorption. Journal Nutrition, 131, 2603-2605.

[30]   Silva, I.T., Mello, A.P.Q. and Damasceno, N.R.T. (2011) Antioxidant and inflammatory aspects of lipoproteins-associated phospholipases A2 (LP-PLA2): A review. Lipids Health Disease, 10, 170.

[31]   Korth, R.M. (2001) Ether-linked phospholipids and hyperlipidemia. Recent Res. Devel. Lipids, S.G. Pandalai Publisher, Transworld Research Network, Trivandrum, 61-70.

[32]   Berenson, G.S., Srinivasan, S.R., Bao, W., Newmann, W.P., Tracy, R.E. and Wattigney, W.A. (1998) Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. New England Journal Medicine, 338, 1650-1656.

[33]   Volek, J.S., Fernandez, M.L., Feinman, R.D. and Phinney, S.D. (2008) Dietary carbohydrate restricition induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partioning, and metabolic syndrome. Progress in Lipid Research, 47, 307-318.

[34]   Bartz, R., Li, W.H., Venable, B.H., Zehmer, J.K., Welti, M.R., Aderson, R.G.W., Liu, P. and Chapman, K.D. (2007) Lipidomics reveals that adiposome store ether lipids and mediate phospholipid traffic. Journal Lipid Research, 48, 837-847.

[35]   Sacks, F.M., Svetkey, L.P., Vollmer, W.M., Appel, L.J., Bray, G.A., Harsha, D., Obarzanek, E., Conlin, P.R., Miller, E.R., Simons-Morton, D.G., Karanja, N. and Lin, P.H.L.N. (2001) DASH-Sodium Collaboration Research Group. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. New England Journal Medicine, 344, 3-10.

[36]   Querzfurth, H.W. (2010) Review article. Mechanism of disease Alzheimer’ disease. New England Journal of Medicine, 362, 329-344.

[37]   Catapano, A.L., Reine, Z., De Backer, G., et al. (2011) ECS/EAS guidelines for the management of dyslipidemias. The task force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). S Humphries Publisher, Atherosclerosis, Suppl. 21751.

[38]   Ambrosio, G., Oriente, A., Napoli, C., Palumbo, G., Chiariello, P., Marone, G., Condorelli, M., Chiariello, M. and Triggiani, M. (1994) Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolized platelet-activating factor. Journal of Clinical Investigation, 93, 2408-2416.

[39]   Tokumura, A., Sumida, T., Toujima, M., Kogure, K., Fukuzawa, K., Takahashi, Y. and Yamamoto, S. (2000) Structural identification of phosphatidylcholines having an oxidatively shortened linoleate residue generated through its oxygenation with soybean or rabbit reticulocyte lipoxygenase. Journal of Lipid Research, 41, 953-962.

[40]   Kraus, A.R. (2008) Alkoholkonsum, alkoholbezogene probleme und trends. Ergebnisse des epidemiologischen suchtsurvey 2003. Robert Koch Institut, Gesundheitsberi-chterstattung des Bundes 2008, Heft 40.

[41]   Aronow, W.S., Fleg, J.L. and Peine, C.J. (2011) ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Journal of the American College of Cardiology, 57, 2037-2114.

[42]   Amareno, P., Goldstein, L.B. and Szarek, M. (2007) Effect of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The stroke prevention by agressive reduction in cholesterol levels (SPARCL) trial. Stroke, 38, 3198-3204.

[43]   Kathiresan, S., Melander, O., Guiduccis, C., Surti, A., Burth, N.P., Rieder, M.J., Cooper, G.M., Roos, C., et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nature Genetic, 40, 189-197.

[44]   Taylor, A.J., Villines, T.C., Stanek, E.J., Devine, D.P., Griffen, L., Miller, M., Weissmann, N.J. and Turco, M. (2009) Extended-release niacin or ezetimibe and carotid intima-media thickness. New England Journal of Medicine, 361, 2113-2122.

[45]   Winkler, K., Abletshauser, C., Friedrich, I., Hoffmann, M.M., Wieland, H. and Marz, W. (2004) Fluvastatin slow-release lowers platelet-activating factor acetylhydrolase activity: A placebo-controlled trial in patients with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism, 89, 1153-1159.

[46]   Vergeer, M., Holleboom, A.G., Kastelein, J.J.P. and Kuivenhoven, J.A. (2010) The HDL hypothesis: Does high-density lipoprotein protect from atherosclerosis. Journal of Lipid Research, 51, 2058-2073.

[47]   The Aim-High-Investigators (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine, 365, 2255-2267.

[48]   Kheras, A.V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M.F., Jafri, K., French, B.C., Phillips, J.A., Mucksavage, M.L., Wilensky, R.L., Mohler, E.R., Rothblatt, G.H. and Rader, D.J. (2011) Cholesterol efflux capacity, high density lipoprotein function and atherosclerosis. New England Journal of Medicine, 364, 127-135.

[49]   Parat, G, Stergiou, G.S., Asmar, R., Bilo, G., de Leeuw, P., Imai, Y., Kario, K., Lurbe, E., Manolis, A., Mengden, T., O’Brien, E., Ohkubo, T., Padfield, P., Palatini, P., Pickering, T.G., Redon, J., Revera, M., Ruilope, L.M., Shennan, A., Staessen, J.A., Tisler, A., Waeber, B., Zanchetti, Mancia, G. and on behalf of ESH Working Group on Blood pressure Monitoring (2010) European society of hypertension practice guidelines for home blood pressure monitoring. Journal of Human Hypertension, 24, 779-785.

[50]   Nofer, J.R., Kehrel, B., Fobker, M., Levkau, B., Assmann, G. and von Eckardstein, A. (2002) HDL and arteriosclerosis: Beyond reverse cholesterol transport. Atherosclerosis, 161, 1-16.

[51]   Fournier, N., Myara, I., Atger, V. and Moatti, N. (1995) Reactivity of lecithin-cholesterol acyltransferase (LCAT) towards glycated high-density lipoproteins (HDL). Clinica Chimica Acta, 234, 47-61.

[52]   Hoang, A., Tefft, C., Duffy, S.J., Formosa, M., Henstridge, D.C., Kingwell, B.A. and Sviridov, D. (2008) ABCA1 expression in humans is associated with physical activity and alcohol consumption. Atherosclerosis, 197, 197-203.

[53]   Korth, R.M. (2005) Gender dyslipidemia and ether phospholipids. FASEB Journal, 19, A109.

[54]   Korth, R.M. (2007) Obesity mediated hypertension while alcohol use declined renal endothelial barriers of women. FASEB Journal, 21, A1361.

[55]   Korth, R.M. (2007) Smoking, borderline LDL levels and renal small vessel disease of women with overweight. Atherosclerosis Supplements, 8, 32-33.

[56]   Korth, R. (2002) Treatment of lyso paf-mediated disorders with lyso paf or paf antagonists and procedure for determining their efficacy. United States Patent Application Publication Pub. No. 2002/0127287 A1.

[57]   Hillege, H.L., Fidler, V., Diercks, G.F.H., van Gilst, W.H., de Zeeuw, D., van Veldhuisen, D.J., Gans, R.O.B., Janssen, W.M.T., Grobbee, D.E., de Jong, P.E. and Prevention of Renal and Vascular End Stage Disease (Prevend) study group (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation, 106, 17777-17782.

[58]   Bosworth, H.B., Olsen, M.K., McCant, F., Harrelsons, M., Gentry, P., Rose, C., Goldstein, M.K., Hoffman, B.B., Powers, B. and Oddone, E.Z. (2007) Hypertension Intervention Nurse Telemedicine Study (HINTS): Testing a multifactoral tailored behavioral/edcuational and a medication management intervention for blood pressure control. American Heart Journal, 153, 918-914.

[59]   Lamarche, B., Uffelmann, K.D., Carpentier, A., Cohn, J.S., Steiner, G., Barrett, P.H. and Lewis, G.F. (1999) Triglyceride enrichement of HDL enhances in vivo metabolic clearance of HDL apo A1 in healthy men. Journal of Clinical Investigation, 103, 1191-1199.

[60]   Marques-Vidal, P., Montaye, M., Haas, B., Bingham, A., Evans, A., Juhan-Vague, I., Ferrières, J., Luc, G., Amouyel, P., Arveiler, D., Yarnell, J., Ruidavets, B.J., Scarabin, P.Y. and Ducimetrière, P. (2001) Relationship between alcoholic beverages and cardiovascular risk factor levels in middle-aged men, the PRIME study. Atherosclerosis, 157, 431-440.

[61]   Adachi, J., Matsushita, S., Yoshioka, N., Funae, R., Fujita, T., Higuchi, S. and Ueno, Y. (2004) Plasma phosphatidylcholine hydroperoxide as a new marker of oxidative stress in alcoholic patients. Journal of Lipid Research, 45, 967-971.

[62]   Hildenbrand, M.F. and Bayerl, T.M. (2005) Differences in the modulation of collective membrane motions by ergosterol, lanosterol, and cholesterol: A dynamic light scattering study. Biophysical Journal, 88, 3360-3367.

[63]   Davies, S.S., Pontsler, A.V., Marathe, G.K., Harrison, K.A., Murphy, R.C., Hinshaw, J.C., Prestwich, G.D., Hilaire, A.S.T., Prescott, S.M., Zimmerman, G.M. and McIntyre, T.M. (2001) Oxidized alkyl phospholipids are specific high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. Journal of Biological Chemistry, 276, 16015-16023.

[64]   Chen, P., Jou, Y.S., Fann, C.S., Chen, J.W., Chung, C.M., Lin, C.Y., Wu, S.Y., Kang, M.J., Chen, Y.C., Jong, Y.S., Lo, H.M., Kang, C.S., Chen, C.S., Chang, H.C., Huangk, N.K., Wu, Y.L. and Pan, W. (2009) Lipoprotein lipase variants associated with an endophenotype of hypertension: Hypertension combined with elevated triglycerides. Human Mutation, 30, 49-55.

[65]   Hiramoto, M., Yoshida, H., Imaizumi, T., Yoshimizu, N. and Satoh, K. (1997) A mutation in plasma platelet activating factor acetylhydrolase (VAL279-Phe) is a genetic risk factor for stroke. Stroke, 28, 2417-2420.

[66]   Casas, J.P., Ninio, E., Panayiotou, A., Palmen, J.M., Cooper, J.A., Ricketts, S.L., Sofat, R., Nicolaides, A.N., Corsett, J.P., Fowkes, F.G., Tzoulaki, I., Kumari, M., Brunner, E.J., Kivimak, M., Marmot, M.G., Hoffmann, M.M., Winkler, K., Märtz, W., Ye, S., Stirnadel, H.A., Boekholdt, S.M., Khaw, K.T., Humphries, S.E., Sandhu, M.S., Hinorani, A.D. and Talmud, P.J. (2010) PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10494 cases and 15 624 controls of European ancestry. Circulation, 121, 2284-2293.

[67]   Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennachio, L.A., Boerwinkle, E., Cohen, J. and Hobbs, H.H. (2008) Genetic variation in PNPLA3 confess susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 40, 1461-1465.

[68]   Nelson, M.R., Wegmann, D., Ehm, G.M., Kessner, D., St Jean, P., Verzilli, C., Shen, J., Tang, Z., Bacanu, S., Fraser, D., Warren, L., Aponte, J., Liu, X., Zhang, H., Zhang, Y., Li, Y., Li, L., Woollard, P., Topp, S., Hall, M., Nangle, K., Wang, J., Abecasis, G., Cardon, L., Zöllner, S., Whittaker, J., Chissoe, S., Novembre, J. and Mooser, V. (2012) An abundance of rare functional variants in 202 drug target genes sequenced in 14002 people. Science, 337, 100-104.